Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
26 studies found for:    Open Studies | Lymphoma OR CLL | CART-19 OR Engineered Lymphocyte Therapy
Show Display Options
Rank Status Study
1 Recruiting Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Intervention: Biological: CART 19
Sponsor: University of Pennsylvania
Number Enrolled: 15
2 Recruiting The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CART-19
Sponsor/Collaborators: Henan Cancer Hospital;   The Beijing Pregene Science and Technology Company, Ltd.
Number Enrolled: 30
3 Recruiting Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Intervention: Biological: CART-19
Sponsor: University of Pennsylvania
Number Enrolled: 57
4 Recruiting Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
Intervention: Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)
Sponsor/Collaborators: University of Pennsylvania;   Children's Hospital of Philadelphia
Number Enrolled: 10
5 Recruiting CART-19 Immunotherapy in Mantle Cell Lymphoma
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
Sponsor: Chinese PLA General Hospital
Number Enrolled: 2
6 Recruiting Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Intervention: Genetic: CTL019
Sponsor/Collaborators: Novartis Pharmaceuticals;   Novartis
Number Enrolled: 130
7 Recruiting Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Interventions: Biological: anti-CD20-CAR vector-transduced autologous T cells;   Other: genetically engineered lymphocyte therapy
Sponsor: Chinese PLA General Hospital
Number Enrolled: 50
8 Recruiting Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
Sponsor: Chinese PLA General Hospital
Number Enrolled: 12
9 Recruiting Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Intervention: Biological: anti-CD19/20-CAR vector-transduced T cells
Sponsor: Chinese PLA General Hospital
Number Enrolled: 20
10 Recruiting CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
Intervention: Biological: CD19 targeted chimeric antigen receptor T cells
Sponsor/Collaborators: Zhejiang University;   Innovative Cellular Therapeutics Co., Ltd.
Number Enrolled: 50
11 Not yet recruiting Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
Intervention: Biological: Adult differentiated autologous T-cells
Sponsor/Collaborators: Sara V. Latorre;   Instituto de Salud Carlos III;   Institut d'Investigacions Biomèdiques August Pi i Sunyer
Number Enrolled: 10
12 Recruiting Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Intervention: Biological: CART-19
Sponsor: Beijing Sanwater Biological Technology Co., Ltd.
Number Enrolled: 20
13 Recruiting A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
Intervention: Genetic: prophylactic 4SCAR19 cells
Sponsor/Collaborators: The First People's Hospital of Yunnan;   Shenzhen Geno-Immune Medical Institute
Number Enrolled: 30
14 Recruiting The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CART-19 cells
Sponsor/Collaborators: Henan Cancer Hospital;   The Beijing Pregene Science and Technology Company, Ltd.
Number Enrolled: 20
15 Recruiting Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Intervention: Biological: CTL019 T-cells
Sponsor/Collaborators: Novartis Pharmaceuticals;   University of Pennsylvania;   Novartis
Number Enrolled: 67
16 Recruiting Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
Intervention: Biological: huCART19
Sponsor: University of Pennsylvania
Number Enrolled: 50
17 Recruiting CART19 in Patient With ALL
Intervention: Biological: CART 19
Sponsor: University of Pennsylvania
Number Enrolled: 24
18 Recruiting Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
Intervention: Biological: CART-19
Sponsor: University of Pennsylvania
Number Enrolled: 24
19 Recruiting Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
Intervention: Biological: CD19CART
Sponsor: Innovative Cellular Therapeutics Co., Ltd.
Number Enrolled: 30
20 Recruiting CART-19 Cells For MRD Positive CD19+ ALL
Intervention: Biological: CART-19
Sponsor: Fujian Medical University
Number Enrolled: 20

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.